This invention relates to medical procedures and apparatus in general, and more particularly to medical procedures and apparatus for sealing an opening in the side wall of a body lumen, and/or for reinforcing a weakness in the side wall of a body lumen, while maintaining substantially normal flow through the body lumen.
The human body consists of many different anatomical structures. Among these anatomical structures are the blood vessels which circulate blood throughout the body, i.e., the arteries which deliver oxygenated blood to the end tissues and the veins which return oxygen-depleted blood from the end tissues.
In some cases, a blood vessel can become weakened, thereby causing the side wall of the blood vessel to balloon outwardly so as to create an aneurysm. See, for example,
Aneurysms can present a serious threat to the patient, since they may enlarge to the point of rupture, thereby resulting in a rapid and uncontrolled loss of blood. Depending upon the size and location of the aneurysm, the aneurysm can be life-threatening.
By way of example but not limitation, an intracranial aneurysm can be fatal if rupture occurs. Given the life-threatening nature of such intracranial aneurysms, these aneurysms have traditionally been treated with an open craniotomy and microsurgical clipping. This procedure generally involves placing a small titanium clip across the neck of the aneurysm, thus isolating the aneurysm from blood flow and inhibiting subsequent rupture (or re-rupture). This clipping procedure is typically done under direct visualization, using an operating microscope.
More recently, minimally-invasive techniques have also been used to treat both ruptured and un-ruptured brain aneurysms. These minimally-invasive techniques generally employ interventional neuroradiological procedures utilizing digital fluoroscopy. More particularly, these interventional neuroradiological procedures generally use X-ray visualization to allow the surgeon to place a microcatheter within the dome of the aneurysm. With the microcatheter in place, detachable coils are then deployed within the dome of the aneurysm, causing thrombosis of the aneurysm so as to prevent subsequent rupture (or re-rupture). However, this coil-depositing procedure has a number of drawbacks, including the risk of coil herniation into the lumen of the blood vessel; the risk of coil migration out of the aneurysm and into the blood vessel, with subsequent downstream migration; the risk of aneurysm rupture; etc.
As a result, a primary object of the present invention is to provide a new and improved device, adapted for minimally-invasive, endoluminal delivery, which may be used to prohibit blood flow to an aneurysm while maintaining substantially normal blood flow through the blood vessel.
Another object of the present invention is to provide an expandable spherical structure, comprising an open frame with a closed face, or an open frame with a face having a high strut density, which may be used to close off an opening in a side wall of a blood vessel while maintaining substantially normal blood flow through the blood vessel.
Another object of the present invention is to provide an expandable spherical structure, comprising an open frame with a closed face, or an open frame with a face having a high strut density, which may be used to reinforce a weakness in a side wall of a blood vessel while maintaining substantially normal blood flow through the blood vessel.
Another object of the present invention is to provide an expandable spherical structure, comprising an open frame with a closed face, or an open frame with a face having a high strut density, which may be used to prohibit fluid flow through an opening in the side wall of a lumen other than a blood vessel, and/or to close off an opening in the side wall of a lumen other than a blood vessel, and/or so as to reinforce a weakness in a side wall of a lumen other than a blood vessel, while maintaining substantially normal flow through the lumen.
Another object of the present invention is to provide an expandable spherical structure which may be used to facilitate the deployment of detachable coils or other embolic material into the interior of an aneurysm while maintaining substantially normal flow through the blood vessel.
These and other objects of the present invention are addressed through the provision and use of a novel expandable spherical structure.
In one form of the invention, there is provided an expandable spherical structure for deployment in a blood vessel or other body lumen, comprising:
an open frame configured to assume a collapsed configuration and an expanded configuration; and
a closed face carried by the open frame;
wherein the open frame is configured so as to permit substantially normal flow therethrough when the open frame is in its expanded configuration, and further wherein the closed face is configured so as to obstruct flow therethrough.
In another form of the invention, there is provided a system for sealing an opening in the side wall of a blood vessel or other body lumen and/or reinforcing a weakness in the side wall or apex of a bifurcation of the blood vessel or other body lumen, while maintaining substantially normal flow through the blood vessel or other body lumen, comprising:
an expandable spherical structure for deployment in the blood vessel or other body lumen, comprising:
an installation tool for carrying the expandable spherical structure to a deployment site, wherein the installation tool comprises:
In another form of the invention, there is provided an endoluminal device for deployment in a blood vessel or other body lumen, comprising:
an expandable sphere-like structure which is collapsible for delivery to a therapy site within the body, wherein the expandable sphere-like structure comprises:
In another form of the invention, there is provided a method for sealing an opening in the side wall of a body lumen while maintaining substantially normal flow through the body lumen, comprising:
providing an expandable spherical structure for deployment in the body lumen, comprising:
delivering the expandable spherical structure to a therapy site within the body lumen while the open frame is in its collapsed configuration; and
transforming the expandable spherical structure from its collapsed configuration to its expanded configuration so that the expandable spherical structure is securely lodged in the body lumen, with the closed face of the expandable spherical structure positioned so as to close off the opening in the side wall of the body lumen and with the open frame permitting flow through the body lumen.
In another form of the invention, there is provided a method for reinforcing a weakness in a side wall of a body lumen while maintaining flow through the body lumen, comprising:
providing an expandable spherical structure for deployment in the body lumen, comprising:
delivering the expandable spherical structure to a therapy site within the body lumen while the open frame is in its collapsed configuration; and
transforming the expandable spherical structure from its collapsed configuration to its expanded configuration so that the expandable spherical structure is securely lodged in the body lumen, with the closed face of the expandable spherical structure positioned so as to reinforce the weakness in a side wall of the body lumen and with the open frame permitting flow through the body lumen.
These and other objects and features of the present invention will be more fully disclosed or rendered obvious by the following detailed description of the preferred embodiments of the invention, which is to be considered together with the accompanying drawings wherein like numbers refer to like parts, and further wherein:
Looking now at
Expandable spherical structure 5 generally comprises a spherical body comprising an open frame 10 with a closed face 15. Preferably open frame 10 and closed face 15 together define the entire exterior shape of the spherical body, with open frame 10 making up the majority of the exterior shape of the spherical body.
In one preferred form of the invention, open frame 10 defines approximately 90% of the exterior shape of the spherical body and closed face 15 defines approximately 10% of the exterior shape of the spherical body. In another preferred form of the invention, open frame 10 defines approximately 80% of the exterior shape of the spherical body and closed face 15 defines approximately 20% of the exterior shape of the spherical body. In yet another preferred form of the invention, open frame 10 comprises approximately 70% of the exterior shape of the spherical body and closed face 15 defines approximately 30% of the exterior shape of the spherical body. And in yet another preferred form of the invention, open frame 10 comprises approximately 60% of the exterior shape of the spherical body and closed face 15 comprises approximately 40% of the exterior shape of the spherical body.
Expandable spherical structure 5 is constructed so that it may be deployed in a blood vessel or other body lumen, by (i) collapsing the expandable spherical structure into a configuration of reduced size, (ii) moving the collapsed structure through the blood vessel or other body lumen to a therapy site, and (iii) expanding the collapsed structure to an enlarged size at the therapy site, whereby to secure the expandable spherical structure in the blood vessel or body lumen so that its closed face 15 is presented to a side wall of the blood vessel or other body lumen, whereby to close off an aneurysm or other opening in the side wall of the blood vessel or other body lumen, or to otherwise reinforce a weakness in the side wall of the blood vessel or other body lumen, without impeding normal flow through the blood vessel or other body lumen.
Significantly, by forming expandable spherical structure 5 in the shape of a spherical body, the endoluminal device is readily centered on the neck of an aneurysm or other opening in a body lumen, with closed face 15 projecting into, and securely sealing, the neck of the aneurysm or other opening in a body lumen.
Furthermore, by forming expandable spherical structure 5 so that it can expand at the therapy site and lodge itself in the blood vessel or other body lumen with its closed face 15 presented to a side wall of the blood vessel or other body lumen, expandable spherical structure 5 is effectively self-sizing, since it can be expanded to the degree necessary to span the blood vessel or other body lumen.
More particularly, expandable spherical structure 5 generally comprises an open frame 10 which has a closed face 15 carried thereon. Open frame 10 is formed so that it can assume a first, collapsed configuration of reduced size (
Significantly, by forming the endoluminal device as an expandable spherical structure, the device can be collapsed to a reduced size for minimally-invasive, endoluminal delivery into a blood vessel or other body lumen, yet can thereafter be expanded to the required size for secure lodgement at the therapy site, whereby to seal off an opening in a body lumen and/or to reinforce a weakness in the side wall of the body lumen. Furthermore, by forming expandable spherical structure 5 in the shape of a spherical body, the endoluminal device is readily centered on the neck of an aneurysm or other opening in a body lumen, with closed face 15 projecting into, and securely sealing, the neck of the aneurysm or other opening in a body lumen. And by forming expandable spherical structure 5 so that it can expand at the therapy site and lodge itself in the blood vessel or other body lumen with its closed face 15 presented to a side wall of the blood vessel or other body lumen, expandable spherical structure 5 is effectively self-sizing, since it expands to the degree necessary to span the blood vessel or other body lumen. Additionally, by forming open frame 10 as an open structure, expandable spherical structure 5 can be disposed in the blood vessel or body lumen without impeding normal flow through the blood vessel or other body lumen (
As noted above, (i) expandable spherical structure 5 generally comprises a spherical body comprising an open frame 10 with a closed face 15; (ii) open frame 10 and closed face 15 together preferably define the entire exterior shape of the spherical body, with open frame 10 making up the majority of the exterior shape of the spherical body; (iii) open frame 10 is capable of being collapsed in size for easy delivery of expandable spherical structure 5 to the therapy site and thereafter expanded in size at the therapy site so as to hold closed face 15 against a side wall of a blood vessel or other body lumen; and (iv) open frame 10 is configured so that it does not significantly impede normal flow through the blood vessel or lumen within which it is deployed.
To this end, open frame 10 is preferably formed with an expandable strut construction, so that it can (i) first assume a configuration of reduced size, so that expandable spherical body 5 can move easily through the body to the therapy site, and (ii) thereafter assume a configuration of expanded size, so that it can be securely retained at the desired location in the blood vessel or other body lumen and press closed face 15 securely against the side wall of the blood vessel or body lumen, whereby to close off an aneurysm or other opening in the blood vessel or other body lumen, or to otherwise reinforce the side wall of the blood vessel or other body lumen. And by forming open frame 10 with an expandable strut construction, open frame 10 is effectively self-sizing, since it expands to the degree necessary to span the blood vessel or other body lumen.
Significantly, by forming open frame 10 with an expandable strut construction, open frame 10 does not significantly impede normal flow through the blood vessel or other body lumen when open frame 10 is in its expanded configuration within the blood vessel or other body lumen.
Thus, for example, in the configuration shown in
In one preferred construction, open frame 10 may be formed out of a shape memory alloy (SMA) such as Nitinol, and a temperature transition may be used to change the configuration of open frame 10. By way of example but not limitation, open frame 10 can be formed so that when it is cooled to a temperature below body temperature, the open frame assumes a collapsed configuration (
Alternatively, open frame 10 can be formed out of a resilient material which can be forcibly compressed into a collapsed configuration, restrained in this collapsed configuration, and thereafter released so that it elastically returns to its expanded configuration. By way of example but not limitation, in this form of the invention, expandable spherical structure 5 might be compressed into a configuration of a reduced size, restrained within a sleeve, delivered to the therapy site within the sleeve, and then released from the sleeve so that it elastically returns to an expanded configuration at the therapy site, whereby to lodge itself in the blood vessel or other body lumen, with its closed face pressed against the side wall of the blood vessel or other body lumen. By way of further example but not limitation, open frame 10 can be formed out of a shape memory alloy (SMA) engineered to form stress-induced martensite (SIM) and thereby exhibit superelastic properties, whereby to permit large shape deformations with elastic return. By way of still further example but not limitation, open frame 10 can be formed out of a suitable polymer which exhibits the desired elastic properties.
In another preferred form of the present invention, open frame 10 is formed with a structure which can be collapsed for delivery to the deployment site and thereafter enlarged to an expanded configuration through the use of an expansion device, e.g., an internal balloon, where the balloon is inflated at the therapy site so as to reconfigure open frame 10 to an expanded condition. This arrangement can be advantageous, since it does not require the open frame to rely on temperature transition or elasticity to expand to its fully expanded configuration (or to any desired expanded configuration less than its fully expanded configuration). Thus, a wide range of well known biocompatible materials (e.g., medical grade stainless steel) may be used to form open frame 10.
Closed face 15 is carried by (e.g., mounted on, formed integral with, or otherwise connected to) open frame 10 so that closed face 15 can be pressed securely against the side wall of the blood vessel or other body lumen within which expandable spherical structure 5 is deployed. Closed face 15 preferably comprises a substantially complete surface or barrier which is capable of closing off an aneurysm or other opening in side wall of a blood vessel or other body lumen, and/or for reinforcing a weakness in the side wall of the blood vessel or other body lumen. Closed face 15 may be formed so as to be substantially rigid or it may be formed so as to be flexible. Closed face 15 preferably has the convex configuration shown in
If desired, expandable spherical structure 5 can have some or all of its elements formed out of an absorbable material, so that some or all of the elements are removed from the therapy site after some period of time has elapsed.
By way of example but not limitation, open frame 10 can be formed out of an absorbable material, and closed face 15 can be formed out of a non-absorbable material, so that only closed face 15 is retained at the therapy site after some period of time has passed. See
It is also possible for the entire expandable spherical structure 5 to be formed out of absorbable material(s), i.e., with both open frame 10 and closed face 15 being formed out of absorbable materials. This type of construction can be advantageous where closed face 15 only needs to be held against the side wall of the blood vessel or other body lumen for a limited period of time, e.g., until aneurysm thrombosis/scarring is complete, or to reinforce the side wall of the blood vessel or other body lumen while healing occurs, etc.
It should also be appreciated that, where both open frame 10 and closed face 15 are absorbable, they may be engineered so as to have different absorption rates, so that they are removed from the therapy site at different times. This may be done by making the various elements out of different materials, or by making the various elements out of different blends of the same materials, etc.
As noted above, expandable spherical structure 5 can be used to close off various types of aneurysms.
Thus, for example,
However, it should also be appreciated that expandable spherical structure 5 may be used to close off a bifurcation aneurysm as well. Thus, for example,
It is also anticipated that expandable spherical structure 5 may be used to close off other types of aneurysms as well, e.g., certain forms of fusiform aneurysms. Where expandable spherical structure 5 is to be used to close off a fusiform aneurysm, closed face 15 may comprise a significantly enlarged surface area, or closed face 15 may comprise two or more separated segments disposed about the lateral portions of open frame 10, etc.
It should be appreciated that open frame 10 can be formed with a variety of different configurations without departing from the scope of the present invention.
In one form of the invention, open frame 10 may be formed out of a plurality of struts arranged in a polygonal array. See, for example,
It is also possible to form open frame 10 with a non-polygonal structure.
Thus, for example, open frame 10 may be formed with a spherical spiral structure, e.g., such as is shown in
It will be appreciated that, with the construction shown in
Various installation tools may be provided to deploy expandable spherical structure 5 within a blood vessel or other body lumen.
Thus, for example, in
As noted above, expandable spherical structure 5 of
If desired, installation tool 100 can be provided with a gripper mechanism to releasably secure expandable spherical structure 5 to installation tool 100, e.g., so as to releasably secure expandable spherical structure 5 to installation tool 100 until after expandable spherical structure 5 has been advanced to the therapy site and has returned to its enlarged configuration, so that it is ready to be left at the therapy site. This gripper mechanism ensures complete control of expandable spherical structure 5 as it is moved out of the installation tool and erected within the body, and also facilitates more precise positioning (e.g., with proper rotation, etc.) of the expandable structure against the side wall of the body lumen.
More particularly, and looking now at
As noted above, expandable spherical structure 5 of FIGS. 27 and 44-46 is well suited for use with bifurcation aneurysms, where the neck of the aneurysm is typically axially-aligned with the direction of approach (see, for example,
If desired, installation tool 100 can be provided with an expansion balloon for expanding the expandable spherical structure from its reduced configuration to its enlarged configuration. More particularly, and looking now at
In the preceding description, expandable spherical structure 5 is described as comprising an open frame 10 having a closed face 15 carried thereon. However, it should be appreciated that for many applications, closed face 15 need not comprise a substantially complete surface or barrier, i.e., closed face 15 may be formed with a face having a sufficiently high strut density to form an effectively closed face or to otherwise achieve a desired purpose. Thus, for example, in
It should also be appreciated that it is possible to form the entire expandable spherical structure 5 out of a single superelastic wire, e.g., a shape memory alloy constructed so as to form stress-induced martensite at body temperatures. By way of example but not limitation, an appropriately blended and treated Nitinol wire may be used. In this form of the invention, the expandable spherical structure 5 can be (i) deformed into a collapsed configuration wherein a single path of the wire is constrained within a restraining cannula, and (ii) thereafter reformed in situ by simply pushing the wire out of the distal end of the restraining cannula, whereupon expandable spherical structure 5 reforms in the blood vessel or other body lumen. This form of the invention is particularly well suited to constructions where closed face 15 is formed with a single, patterned strut arranged to have a high strut density, e.g., with a strut density sufficiently high to occlude the mouth of an aneurysm, and/or a strut density sufficiently high to reinforce the side wall of a blood vessel or other body lumen, and/or a strut density sufficiently high to achieve some other desired purpose. See, for example,
It should also be appreciated that expandable spherical structure 5 may be deployed within the body of an aneurysm, so that its closed face 15 confronts the lumen, rather than within the lumen so that its closed face confronts the body of the aneurysm. See, for example,
Again, the expandable spherical structure 5 may be positioned within the interior of a lateral aneurysm (
It is also possible to provide expandable spherical structure 5 with stabilizing legs. More particularly, and looking now at
In the foregoing disclosure, expandable spherical structure 5 is described as comprising a spherical body. In this regard, it should be appreciated that the term “spherical” is intended to mean a true spherical shape, and/or a substantially spherical shape, and/or a near spherical shape, and/or an effectively spherical shape, and/or a generally spherical shape, and/or a polyhedron which approximates a sphere, and/or a shape which approximates a sphere, and/or a structure comprising a substantial portion of any of the foregoing, and/or a structure comprising a combination of any of the foregoing, etc.
Thus, for example, expandable spherical structure 5 may include a first section that constitutes a portion of a sphere and a second section which roughly approximates the remaining portion of a sphere.
It will be appreciated that still further embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure. It is to be understood that the present invention is by no means limited to the particular constructions herein disclosed and/or shown in the drawings, but also comprises any modifications or equivalents within the scope of the invention.
This patent application claims benefit of pending prior U.S. Provisional Patent Application Ser. No. 61/007,189, filed Dec. 11, 2007 by Howard Riina et al. for DEPLOYABLE BLOCKING SPHERE, which patent application is hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5607445 | Summers | Mar 1997 | A |
5645558 | Horton | Jul 1997 | A |
5669933 | Simon et al. | Sep 1997 | A |
5766219 | Horton | Jun 1998 | A |
5772668 | Summers et al. | Jun 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5830222 | Makower | Nov 1998 | A |
5836968 | Simon et al. | Nov 1998 | A |
5851537 | Alberts et al. | Dec 1998 | A |
5911731 | Pham et al. | Jun 1999 | A |
5925060 | Forber | Jul 1999 | A |
5951599 | McCrory | Sep 1999 | A |
6013854 | Moriuchi | Jan 2000 | A |
6068638 | Makower | May 2000 | A |
6090125 | Horton | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6136015 | Kurz et al. | Oct 2000 | A |
6159165 | Ferrera et al. | Dec 2000 | A |
6159225 | Makower | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165198 | McGurk et al. | Dec 2000 | A |
6171326 | Ferrera et al. | Jan 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6221086 | Forber | Apr 2001 | B1 |
6231587 | Makower | May 2001 | B1 |
6283951 | Flaherty et al. | Sep 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6302875 | Makower et al. | Oct 2001 | B1 |
6309415 | Pulnev et al. | Oct 2001 | B1 |
6322576 | Wallace et al. | Nov 2001 | B1 |
6325820 | Khosravi et al. | Dec 2001 | B1 |
6330884 | Kim | Dec 2001 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6368338 | Konya et al. | Apr 2002 | B1 |
6375615 | Flaherty et al. | Apr 2002 | B1 |
6379319 | Garibotto et al. | Apr 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6432127 | Kim et al. | Aug 2002 | B1 |
6482222 | Bruckheimer et al. | Nov 2002 | B1 |
6540657 | Cross, III et al. | Apr 2003 | B2 |
6544230 | Flaherty et al. | Apr 2003 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6569179 | Teoh et al. | May 2003 | B2 |
6579311 | Makower | Jun 2003 | B1 |
6585748 | Jeffree | Jul 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592605 | Lenker et al. | Jul 2003 | B2 |
6605111 | Bose et al. | Aug 2003 | B2 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6613081 | Kim et al. | Sep 2003 | B2 |
6616617 | Ferrera et al. | Sep 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6635069 | Teoh et al. | Oct 2003 | B1 |
6638291 | Ferrera et al. | Oct 2003 | B1 |
6638293 | Makower et al. | Oct 2003 | B1 |
6652555 | Van Tassel et al. | Nov 2003 | B1 |
6652556 | Van Tassel et al. | Nov 2003 | B1 |
6655386 | Makower et al. | Dec 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660024 | Flaherty et al. | Dec 2003 | B1 |
6685648 | Flaherty et al. | Feb 2004 | B2 |
6689150 | Van Tassel et al. | Feb 2004 | B1 |
6695876 | Marotta et al. | Feb 2004 | B1 |
6709444 | Makower | Mar 2004 | B1 |
6726677 | Flaherty et al. | Apr 2004 | B1 |
6730108 | Van Tassel et al. | May 2004 | B2 |
6746464 | Makower | Jun 2004 | B1 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6790218 | Jayaraman | Sep 2004 | B2 |
6811560 | Jones et al. | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6860893 | Wallace et al. | Mar 2005 | B2 |
6863684 | Kim et al. | Mar 2005 | B2 |
6872218 | Ferrera et al. | Mar 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6894092 | Sylvester | May 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6929009 | Makower et al. | Aug 2005 | B2 |
6929654 | Teoh et al. | Aug 2005 | B2 |
6949113 | Van Tassel et al. | Sep 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6984240 | Ken et al. | Jan 2006 | B1 |
7059330 | Makower et al. | Jun 2006 | B1 |
7094230 | Flaherty et al. | Aug 2006 | B2 |
7134438 | Makower et al. | Nov 2006 | B2 |
7159592 | Makower et al. | Jan 2007 | B1 |
7179270 | Makower | Feb 2007 | B2 |
7211107 | Bruckheimer et al. | May 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7241310 | Taylor et al. | Jul 2007 | B2 |
7279000 | Cartier et al. | Oct 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7303571 | Makower et al. | Dec 2007 | B2 |
7306622 | Jones et al. | Dec 2007 | B2 |
7306624 | Yodfat et al. | Dec 2007 | B2 |
7316655 | Garibotto et al. | Jan 2008 | B2 |
7316701 | Ferrera et al. | Jan 2008 | B2 |
7326225 | Ferrera et al. | Feb 2008 | B2 |
7407506 | Makower | Aug 2008 | B2 |
7572288 | Cox | Aug 2009 | B2 |
7879064 | Monstadt et al. | Feb 2011 | B2 |
8088171 | Brenneman | Jan 2012 | B2 |
8092515 | Johnson et al. | Jan 2012 | B2 |
8372110 | Monstadt et al. | Feb 2013 | B2 |
20010012961 | Deem et al. | Aug 2001 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20020193812 | Patel et al. | Dec 2002 | A1 |
20020193813 | Helkowski et al. | Dec 2002 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030055451 | Jones et al. | Mar 2003 | A1 |
20030109917 | Rudin et al. | Jun 2003 | A1 |
20030139802 | Wulfman et al. | Jul 2003 | A1 |
20030216804 | DeBeer et al. | Nov 2003 | A1 |
20040006383 | Zilla et al. | Jan 2004 | A1 |
20040034386 | Fulton et al. | Feb 2004 | A1 |
20040087998 | Lee et al. | May 2004 | A1 |
20040098030 | Makower et al. | May 2004 | A1 |
20040153142 | Klumb et al. | Aug 2004 | A1 |
20040172056 | Guterman et al. | Sep 2004 | A1 |
20040181253 | Sepetka et al. | Sep 2004 | A1 |
20040210298 | Rabkin et al. | Oct 2004 | A1 |
20040260384 | Allen | Dec 2004 | A1 |
20050107823 | Leone et al. | May 2005 | A1 |
20050187564 | Jayaraman | Aug 2005 | A1 |
20050192618 | Porter | Sep 2005 | A1 |
20050192619 | Teoh et al. | Sep 2005 | A1 |
20060047299 | Ferguson | Mar 2006 | A1 |
20060052816 | Bates et al. | Mar 2006 | A1 |
20060116625 | Renati et al. | Jun 2006 | A1 |
20060116709 | Sepetka et al. | Jun 2006 | A1 |
20060116712 | Sepetka et al. | Jun 2006 | A1 |
20060135947 | Soltesz et al. | Jun 2006 | A1 |
20060142845 | Molaei et al. | Jun 2006 | A1 |
20060200234 | Hines | Sep 2006 | A1 |
20060224183 | Freudenthal | Oct 2006 | A1 |
20060241686 | Ferrera et al. | Oct 2006 | A1 |
20070060994 | Gobran et al. | Mar 2007 | A1 |
20070083257 | Pal et al. | Apr 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070219619 | Dieck et al. | Sep 2007 | A1 |
20070239261 | Bose et al. | Oct 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20080039933 | Yodfat et al. | Feb 2008 | A1 |
20080045995 | Guterman et al. | Feb 2008 | A1 |
20080114391 | Dieck et al. | May 2008 | A1 |
20080114436 | Dieck et al. | May 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20090062834 | Moftakhar et al. | Mar 2009 | A1 |
20090069836 | Labdag et al. | Mar 2009 | A1 |
20090125053 | Ferrera et al. | May 2009 | A1 |
20090297582 | Meyer et al. | Dec 2009 | A1 |
Number | Date | Country |
---|---|---|
1216929 | May 1999 | CN |
2001-212152 | Aug 2001 | JP |
2007-536943 | Dec 2007 | JP |
WO 9727893 | Aug 1997 | WO |
WO 2005072196 | Aug 2005 | WO |
WO 2006032289 | Mar 2006 | WO |
WO 2006091195 | Aug 2006 | WO |
WO 2008022327 | Feb 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20090264914 A1 | Oct 2009 | US |
Number | Date | Country | |
---|---|---|---|
61007189 | Dec 2007 | US |